Serving microbiome innovators as the best-in-class CDMO means keeping our fingertips on the pulse of the industry. Discover what's new and what's next in this fast-moving field.
LATEST MICROBIOME INDUSTRY NEWS
MARCH 2021
Tumour neoantigen mimicry by microbial species in cancer immunotherapy - Nature
Single strain control of microbial consortia - Nature
The microbiome and human cancer - Science
Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and closes Series B Equity Financing
4D pharma Announces Completion of Merger With Longevity Acquisition Corporation - Business Wire
MaaT links microbiome drug to GvHD responses, plans phase 3 - FierceBiotech
Modulating gut microbiota to treat cancer - Science
Ecology-guided prediction of cross-feeding interactions in the human gut microbiome - Nature
Dissecting the contribution of host genetics and the microbiome in complex behaviors - Cell
Associations between the gut microbiome and fatigue in cancer patients - Scientific Reports
The microbiome and human cancer - Science
Single strain control of microbial consortia - Nature Communications
FEBRUARY 2021
Coming Soon: Reserve a copy of our upcoming white paper.
Videos, presentations, and interviews with our subject matter experts.
We're always open to engaging with individuals interested in our company or the microbiome therapy market in general.
We look forward to hearing from you.
Headquarters &
cGMP Manufacturing
650 Pleasant Street
Watertown, MA 02472
Process Development
& cGMP Manufacturing
1622 NW 55th Pl.
Gainesville, FL 32653
For CDMO Service Inquiries: bd@arrantabio.com